MedWorm provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest medical blog items that have been tagged with 'actavis'. Sat, 03 Sep 2011 02:50:42 +0100 http://www.medworm.com/index.php?rid=4968912&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FK90Sx9ix8RI%2F In a closely watched case, the US Supreme Court has ruled that generic drugmakers are not required to strengthen product labeling if alerted to side effects, even when the same change has not been made to the labeling for the branded med. However, the court was divided with a 5-to-4 majority deciding in favor of the argument made by the generic industry. The decision came in response to a pair of lawsuits by two women who claimed such changes could have been made under state law and without FDA approval for such changes. They argued generic drugmakers would create uncertainty about safety if they are not held liable under state laws and update labeling in the face of evidence of serious side effects. Generic drugmakers, including Actavis and Pliva, argued they would have been required to p... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4968912 Thu, 23 Jun 2011 15:16:43 +0100 4968912 http://www.medworm.com/index.php?rid=4642995&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FuZGC-ukK-wc%2F Should generic drugmakers be required to strengthen product labeling if alerted to side effects, even when the same change has not been made to the labeling for the branded med? This question goes to the heart of a pair of state lawsuits filed by two women, who claim generic drugmakers should be held liable for failing to warn of serious side effects. However, the drugmakers, which include Actavis and Pliva, claim federal law preempts the lawsuits, because they would be required to offer labeling that is different from what appears on the label of the brand-name drug. The generic drugmakers further maintain that permitting such lawsuits to proceed in state courts would raise their costs, which would, ultimately, be passed on to consumers. This complicated issue will be heard this coming We... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4642995 Mon, 28 Mar 2011 13:12:39 +0100 4642995 http://www.medworm.com/index.php?rid=4433059&cid=t_145982_87_f&fid=34765&url=http%3A%2F%2Fhcrenewal.blogspot.com%2F2011%2F02%2Fmore-legal-theater-actavis-convicted.html The march of legal settlements, and guilty pleas and verdicts continues.  The latest on parade, in alphabetical order, are:ActavisAs reported by the (Austin, Texas) American-Statesman:In what state officials describe as a record-setting verdict, a Travis County jury found Tuesday that a global drug manufacturer misrepresented prices to the state's Medicaid program and said the company should pay the state and federal government $170.3 million.The verdict concluded a nearly three-week trial in state district court, where lawyers for the Texas attorney general's office argued that Actavis Mid-Atlantic LLC and co-defendant Actavis Elizabeth LLC artificially inflated the costs of medications to obtain more money. Medicaid reimbursed pharmacies at higher rates because of the falsely report... Health Care Renewal blogs http://www.medworm.com/rss/comments.php?id=4433059 Thu, 03 Feb 2011 21:13:00 +0100 4433059 http://www.medworm.com/index.php?rid=4424440&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FEULF20iWYcU%2F Actavis has become the latest drugmaker ordered to tens of millions of dollars over Medicaid fraud after a Texas jury determined that reported prices for its medications were artificially inflated. The $170 million verdict came as the result of a whistleblower lawsuit brought against several drugmakers by the Texas attorney general two years ago (here it is). As with several such lawsuits against drugmakers, the whistleblower was Ven-A-Care of the Florida Keys, a pharmacy that has helped federal and state prosecutors probe fraudulent Medicaid pricing for the last several years by analyzing data. Its efforts have resulted in settlements in nearly 20 cases and yielded the pharmacy nearly $400 milliion for its trouble. Among the drugmakers that have recently struck deals are Mylan Labs (read ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4424440 Tue, 01 Feb 2011 22:10:35 +0100 4424440 http://www.medworm.com/index.php?rid=4377787&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FcjCmn3mBJKE%2F Two years ago, the US Federal Trade Commission filed a highly publicized lawsuit against Cephalon over pay-to-delay deals worth an estimated $200 million with some generic drugmakers - Ranbaxy Labs, Mylan Labs and Teva Pharmaceuticals - to keep a copycat version of its Provigil sleep-disorder pill off the market until 2012 (read this). Now, though, more than three dozen other drugmakers have raced to court to try to keep details of their own deals from being disclosed as a result of this battle. In a motion filed in federal court in Philadelphia this week, no fewer than 37 drugmakers - including Abbott Laboratories, Merck, Novartis, Bristol-Myers Squibb, Sanofi-Aventis, GlaxoSmithKline, Pfizer, Bayer, AstraZeneca, Johnson & Johnson, Actavis, Waston Pharmaceuticals, Dr. Reddy’s, ... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4377787 Thu, 20 Jan 2011 20:48:02 +0100 4377787 http://www.medworm.com/index.php?rid=4343328&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2Fy_nfZpM3GEM%2F A whistleblower lawsuit filed in 2002 has been unsealed and reveals that nearly two dozen drugmakers have been accused of selling unapproved prescription meds for years. Of course, such charges must still be proven, but the US Department of Justice did get involved in pursuing three other companies - Forest Laboratories (read here), Schwarz Pharma and Eon Laboratories - originally named in the lawsuit and reached settlements. What will happen from here is unclear. But for one other company, the DOJ has declined to intervene, or join, the lawsuit in pursuit of the rest of the drugmakers, including Abbott Laboratories, Actavis, Mylan Laboratories, Shire Pharmaceuticals, Watson Pharmaceuticals and Teva Laboratories. Nonetheless, the lawsuit offers some disturbing details in so far as that una... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=4343328 Thu, 13 Jan 2011 23:30:41 +0100 4343328 http://www.medworm.com/index.php?rid=3280193&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeedproxy.google.com%2F%7Er%2FPharmalot%2F%7E3%2FKINRaaS55OE%2F Top of the morning to you and nice to see you again. The sun is shining here on the Pharmalot corporate campus, where the short people are fast asleep, enjoying a week-long respite from the demands of the local schoolhouse. We, however, are fully immersed in our usual routine and, so, have rummaged around to find a few interesting items to help you motor through the day. Have a good one… Cholesterol Drugs Raise Diabetes Risk By 9% (Bloomberg News) Novartis VC Arms Backs Universal Flu Firm (Reuters) Arkansas To Get $18.5M In Lilly Zyprexa Settlement (Associated Press) Teva & Actavis May Be Final Ratiopharm Bidders (Bloomberg News) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=3280193 Wed, 17 Feb 2010 12:51:37 +0100 3280193 http://www.medworm.com/index.php?rid=1961224&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F452971264%2F Somehow, we forgot to hit the send button earlier. So our usual morning greeting is appearing a bit out of sync. Apologies, everyone. As we wrote… And so the end of the week is upon us. What will you be doing this weekend? Taking in a movie? Throwing a football around? Puttering around the mansion? Our choice - raking leaves, which is good exercise, after all. Whatever your pleasure, we hope you enjoy. Meanwhile, here are a few items to digest as you prepare… Lupin Plant Slammed By FDA Inspectors (The Economic Times) Four Drug Combo Helps With Lung Cancer (Reuters) Actavis Unit Sued By FDA (Bloomberg News) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1961224 Fri, 14 Nov 2008 12:20:12 +0100 1961224 http://www.medworm.com/index.php?rid=1683435&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F357332314%2F Self-medication gets another nod of approval from the Medicines and Healthcare products Regulatory Agency, which will allow anyone 16 years and older to buy a pill for chlamydia, a sexually transmitted disease, without a prescription. The oral antibiotic in question is azithromycin, which is sold as Clamelle by Iceland’s Actavis. “Chlamydia is the most common sexually transmitted disease in the UK. Up to 70 percent of people who have chlamydia have no symptoms and could therefore remain undiagnosed. This means that they are at huge risk of serious long-term health complications, including infertility and ectopic pregnancy,” June Raine, MHRA’s director of rigilance and risk management, says in a statement. The UK has increasingly encouraged self-medication as a way to in... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1683435 Wed, 06 Aug 2008 11:42:36 +0100 1683435 http://www.medworm.com/index.php?rid=1677366&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F355247465%2F Welcome to the working week. We hope your weekend was pleasant enough. Ours was just dandy, although we never did get around to some of those chores. Now, though, the routine returns. Never mind that this is the middle of the summer - meetings and deadlines beckon. So grab a cup of something and dig in. Here are a few items to help the process get under way… Pfizer May Open R&D Facility In Hungary (Portfolio.hu) Gilead AIDS Drugs To Be Tested For Prevention (Bloomberg News) Mum Will Take Vaccine Case To Human Rights Court (The Press & Journal) Actavis Tells Pharmacies, Hospitals To Return Drug (Associated Press) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1677366 Mon, 04 Aug 2008 11:35:52 +0100 1677366 http://www.medworm.com/index.php?rid=1616435&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F332781572%2F A growing number of lawsuits have been filed against the Icelandic drug maker over charges that its recalled heart med was dangerous and defective, and led to one death, the Associated Press reports. Here is the latest suit. The ligitation occurs not longer after Actavis this past April began a nationwide recall of all strengths of the Digitek pills, which are distributed by Mylan Pharmaceuticals and UDL Laboratories. Those two drugmakers were also named as defendants, and similar lawsuits have been filed in West Virginia and California. Actavis said at the time that some tablets may have been double the usual thickness and so would contain twice the active ingredient, posing a risk of toxicity with symptoms from nausea and dizziness to low blood pressure and cardiac instability. The drugm... Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1616435 Fri, 11 Jul 2008 15:46:28 +0100 1616435 http://www.medworm.com/index.php?rid=1407371&cid=t_145982_117_f&fid=36026&url=http%3A%2F%2Fblog.healthtalk.com%2Fzimney%2Fdigoxin-tablets-recalled-over-safety-concerns%2F There’s important news for people who take digoxin, which is a heart medicine also known as digitalis that is most often prescribed for the heart rhythm disturbances called atrial fibrillation and atrial flutter. It is less commonly used to treat heart failure. A nationwide recall of all lots of certain generic brands of digoxin, was announced on April 25, 2008 by the drug’s manufacturer, a company called Actavis Totowa, which was formerly known as Amide Pharmaceuticals. And to make matters more complex, the product is distributed by Mylan Pharmaceuticals as Digitek and by UDL Laboratories as Bertek. The problem is that some digoxin tablets made by Actavis may contain twice the amount of active ingredient as they are supposed to. This is of particular concern because digitalis toxicity... Dr. Z's Medical Report blogs http://www.medworm.com/rss/comments.php?id=1407371 Tue, 29 Apr 2008 17:26:04 +0100 1407371 http://www.medworm.com/index.php?rid=1242299&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F237528177%2F And welcome back to those of you who had an extended weekend. Hope you enjoyed whatever it was you did. But now, back to business. Although we might add that, since schools are closed this week, we may post sporadically today as we tend to the needs of one or more short people. We hope you understand. Meanwhile, here are a few items we’ve just spotted. Catch you soon… More Fentanyl Patches Are Recalled (Yahoo/AP) Roche Completes Offer For Ventana Medical (Bloomberg News) Denmark’s Pharmexa Looking At ‘Strategic Alternatives’ (PharmaTimes) (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=1242299 Tue, 19 Feb 2008 12:15:07 +0100 1242299 http://www.medworm.com/index.php?rid=996643&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F178172662%2F Another day gets under way. The dog has pooped and one of the short people is already at school. And so the way is clear to provide some interesting items. Hope your day is pleasant…. AstraZeneca Says Cobalt Files To Sell Generic Crestor (Bloomberg News) SEC Charges Former Invitrogen Scientist With Insider Trading (Yahoo/Reuters) Elan Sues Actavis Unit Over ADHD Drug Patents (The Independent) Statins May Reduce Prostate Cancer Relapse Risk (PharmaTimes) Studies Clarify How Tamiflu Affects The Brain (The Daily Yomiuri) Eisai Delays Launch Of New Drugs (Bloomberg News) Dr. Reddy’s Eyes Emerging Markets (The Business Standard) LATE ADDITION: Medco Reports Increased Profits (Yahoo/AP) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=996643 Thu, 01 Nov 2007 10:28:19 +0100 996643 http://www.medworm.com/index.php?rid=856916&cid=t_145982_150_f&fid=35777&url=http%3A%2F%2Ffeeds.feedburner.com%2F%7Er%2FPharmalot%2F%7E3%2F154547933%2F A new week gets under way. And so this is an opportunity to catch up on events. Here are some worth noting…. Lundbeck Looking To Buy Other Companies In US (AFX/Thomson Financial) Actavis Makes FDA Filing Challenging King Patent (MarketWatch) India May Add More Drugs To Price-Controlled List (The Economic Times) Teva Must Stop Selling Generic Famvir (Bloomberg News) Cipla Sales Hurt By NGOs (BusinessWeek) Share / E-mail (Source: Pharmalot) Pharmalot blogs http://www.medworm.com/rss/comments.php?id=856916 Mon, 10 Sep 2007 11:12:26 +0100 856916